Literature DB >> 25433417

Choroidal neovascularization secondary to choroideremia.

J Campos-Pavón1, J L Torres-Peña2.   

Abstract

CASE REPORT: The case is presented of a 30 year-old man, with night blindness and decreased visual acuity (VA) in both eyes, but more significant in the left eye (LE) of 20/100. Lesions consistent with choroideremia and LE macular hemorrhage was observed in the fundus. CNV was confirmed by OCT. A definitive diagnosis was obtained by genetic study. No treatment was given as the patient did not return. At 6 months there was a regression of CNV with VA 20/25 in the LE.
CONCLUSIONS: CNV associated with choroideremia is uncommon. Treatment would antiangiogenic therapy, however spontaneous resolution is possible.
Copyright © 2013 Sociedad Española de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Choroidal neovascularization; Choroideremia; Coroideremia; Neovascularización coroidea

Mesh:

Substances:

Year:  2014        PMID: 25433417     DOI: 10.1016/j.oftal.2014.03.012

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  3 in total

1.  Detailed functional and structural phenotype of Bietti crystalline dystrophy associated with mutations in CYP4V2 complicated by choroidal neovascularization.

Authors:  Nicole M Fuerst; Leona Serrano; Grace Han; Jessica I W Morgan; Albert M Maguire; Bart P Leroy; Benjamin J Kim; Tomas S Aleman
Journal:  Ophthalmic Genet       Date:  2016-03-30       Impact factor: 1.803

2.  Spontaneous Regression of Choroidal Neovascularization in a Patient with Pattern Dystrophy.

Authors:  Anastasios Anastasakis; Flamur Goleni; Gerasimos Livir-Rallatos; Charalampos Livir-Rallatos; Panagiotis Zafirakis; Gerald Allen Fishman
Journal:  Case Rep Ophthalmol Med       Date:  2016-10-26

3.  Pathogenic mechanisms and the prospect of gene therapy for choroideremia.

Authors:  Ioannis S Dimopoulos; Stephanie Chan; Robert E MacLaren; Ian M MacDonald
Journal:  Expert Opin Orphan Drugs       Date:  2015-07-01       Impact factor: 0.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.